The goal of this clinical trial is to compare a placebo (a look-alike substance that contains no active drug) with a commonly used antibiotic in children with Mycoplasma pneumoniae (a specific bacterium) induced community-acquired pneumonia. The main question it aims to answer is: Is antibiotic treatment needed in Mycoplasma pneumoniae (a specific bacterium) induced pneumonia? Participants will receive either a placebo or a antibiotic treatment and track their symptoms and vital signs until they are healthy. Researchers will then compare the length of symptoms between the placebo and the antibiotic group.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Co-primary outcome: days to normalization of all vital signs
Timeframe: From enrollment until normalization of all vital signs for at least 24h assessed up to 28 days.
Co-primary outcome: community-acquired pneumonia(CAP)-related change in patient care status
Timeframe: From enrollment assessed up to 28 days.
Patrick M Meyer Sauteur, PD Dr. Dr. med.